Since October, the change of senior executives in the pharmaceutical industry has continued, and many pharmaceutical companies such as Boya Biologics, Yifan Pharmaceutical, and Meinian Health have reported the departure of senior executives, and two vice presidents of pharmaceutical companies have resigned
within one day.
On October 9, Yifan Pharmaceutical announced that the company's board of directors recently received a written resignation report
from Vice President Wang Jie.
After reaching a consensus with the company, Wang Jie applied to resign as vice president of the company, and after resigning from the company, he will no longer hold any position
in the company and its subsidiaries.
As of the disclosure date of this announcement, Wang Jie does not hold shares in the Company, nor does he have any commitments that should be fulfilled but have not been fulfilled
.
According to the 2022 semi-annual report, Yifan Pharmaceutical is mainly engaged in the research and development, production, sales and drug promotion services
of pharmaceutical products, APIs and polymer materials.
In the first half of 2022, the company achieved revenue of 1.
769 billion yuan, down 25.
58% year-on-year; Achieved a net profit of 161 million, down 24.
67%
year-on-year.
On the same day, Meinian Health announced that Ms.
Lin Qing applied to resign as vice president and secretary of the board of directors of the company for personal reasons, and no longer held any position in
the company after resignation.
Up to now, Ms.
Lin Qing has not directly held shares in the company except for some shares held through the 2021 employee stock ownership
plan.
According to the annual report, Lin Qing has been the vice president and secretary of the board of directors of Meinian Health since October 15, 2021, and the term of office is terminated on October 14, 2024, and his pre-tax remuneration is 265,400 yuan
.
According to the data, Meinian Health is mainly engaged in health examination business, with health examination as the core, integrating health consultation, health assessment, and health intervention, and based on health big data, focusing on professional prevention, health security, medical butler services and other fields, providing higher quality health management services
for enterprises and individual customers.
According to the semi-annual report of 2022, the company achieved revenue of 2.
922 billion yuan in the first half of the year, down 13.
67% year-on-year; Net profit attributable to shareholders of listed companies - 666 million yuan, down 56.
3%
year-on-year.
Judging from the time that the above two pharmaceutical executives took office in the departing company, it was less than one year, of which Wang Jie, vice president of Yifan Pharmaceutical, was even less than half a year
from the beginning to the departure.
Behind the acceleration of changes in pharmaceutical executives, it can be seen that the changes in the pharmaceutical industry are also accelerating
.
According to incomplete statistics, more than 30 executives left in September, more than 30 executives left in August, and more than 40 pharmaceutical executives resigned in July.
.
.
Since the beginning of this year, more than 250 executives in the pharmaceutical industry have announced their departures, and almost every day executives have "left", including a large number of vice presidents, deputy general managers and other positions
.
For example, on September 23, Guangyuyuan announced that vice president Miao Hui resigned as vice president of the company due to work
adjustments.
On September 19, Xinhua Pharmaceutical announced the departure of a number of senior executives, including a number of deputy general managers: He Tongqing resigned as deputy general manager due to work adjustments, and still served as a director of the company after resigning; Wang Xiaolong resigned as deputy general manager due to job changes; Du Deqing resigned as deputy general manager due to job changes
.
Haizheng Pharmaceutical announced on August 31 that the company's board of directors received a written resignation report
submitted by Mr.
Zhao Lei, senior vice president of the company, on August 30, 2022.
Mr.
Zhao Lei applied to resign as Senior Vice President of the Company due to personal reasons
.
On August 30, TusS Pharmaceutical announced that the board of directors recently received a written resignation report
submitted by Liu Bingcheng, vice president of the company.
Liu Bingcheng applied to resign as vice president due to job adjustments, and after his resignation, Liu Bingcheng still held other positions in the
company.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
